Candriam SCA’s Trillium Therapeutics Inc. TRIL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-1,150,280
| Closed | -$20.2M | – | 907 |
|
|
2021
Q3 | $20.2M | Buy |
1,150,280
+360,182
| +46% | +$4.21M | 0.14% | 175 |
|
|
2021
Q2 | $7.66M | Buy |
790,098
+790,056
| +1,881,086% | +$7.44M | 0.05% | 328 |
|
|
2021
Q1 | $0 | Buy |
+42
| New | +$519 | ﹤0.01% | 824 |
|
|
2018
Q4 | – | Sell |
-94,000
| Closed | -$538K | – | 860 |
|
|
2018
Q3 | $538K | Hold |
94,000
| – | – | 0.01% | 700 |
|
|
2018
Q2 | $565K | Hold |
94,000
| – | – | 0.01% | 682 |
|
|
2018
Q1 | $672K | Hold |
94,000
| – | – | 0.01% | 645 |
|
|
2017
Q4 | $683K | Sell |
94,000
-16,000
| -15% | -$133K | 0.01% | 640 |
|
|
2017
Q3 | $559K | Hold |
110,000
| – | – | 0.01% | 647 |
|
|
2017
Q2 | $476K | Hold |
110,000
| – | – | 0.01% | 661 |
|
|
2017
Q1 | $677K | Hold |
110,000
| – | – | 0.01% | 618 |
|
|
2016
Q4 | $624K | Hold |
110,000
| – | – | 0.01% | 587 |
|
|
2016
Q3 | $1.63M | Hold |
110,000
| – | – | 0.04% | 399 |
|
|
2016
Q2 | $969K | Hold |
110,000
| – | – | 0.03% | 445 |
|
|
2016
Q1 | $1.02M | Hold |
110,000
| – | – | 0.03% | 426 |
|
|
2015
Q4 | $1.37M | Hold |
110,000
| – | – | 0.04% | 347 |
|
|
2015
Q3 | $1.35M | Hold |
110,000
| – | – | 0.03% | 393 |
|
|
2015
Q2 | $2.38M | Buy |
+110,000
| New | +$2.51M | 0.05% | 337 |
|
Other funds holding TRIL
Candriam SCA's TRIL Position: Q4 2021 in Review
Candriam SCA sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 1,150,280 shares — an estimated $20.2M sold.
Candriam SCA first reported a position in TRIL in Q2 2015 and held it in 17 quarters. The position peaked at $20.2M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.
- Candriam SCA reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
- Candriam SCA sold 1,150,280 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $20.2M.
- Candriam SCA first reported a position in Trillium Therapeutics Inc. in Q2 2015 and held it in 17 quarters.
- Candriam SCA's Trillium Therapeutics Inc. position peaked at $20.2M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.
Based on Candriam SCA's 13F filing for Q4 2021, filed 10 Feb 2022.